Evidence map›Paper›PMID 32276641›Full record

ArticleCell communication and signaling : CCS2020

A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas.

Monika Wimmer, Roland Zauner, Michael Ablinger, Josefina Piñón-Hofbauer, Christina Guttmann-Gruber, Manuela Reisenberger, Thomas Lettner, Norbert Niklas, Johannes Proell, Mila Sajinovic and 9 more

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. AberrantJournal of dental sciences · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Monika WimmerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Roland ZaunerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Michael AblingerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Josefina Piñón-HofbauerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Christina Guttmann-GruberEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Manuela ReisenbergerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Thomas LettnerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Norbert NiklasRed Cross Transfusion Service of Upper Austria, 4020, Linz, Austria.
Johannes ProellCenter for Medical Research, Medical Faculty, Johannes-Kepler-University, 4020, Linz, Austria.
Mila SajinovicMedical Oncology, Ingham Institute for Applied Medical Research, Liverpool, NSW, 2170, Australia.
Paul De SouzaMedical Oncology, Ingham Institute for Applied Medical Research, Liverpool, NSW, 2170, Australia.
Stefan HainzlEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Thomas KocherEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Eva M MurauerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Johann W BauerEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Dirk StrunkInstitute of Experimental & Clinical Cell Therapy, Paracelsus Medical University, 5020, Salzburg, Austria.
Julia ReicheltEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria.
Albert Sleiman MellickMedical Oncology, Ingham Institute for Applied Medical Research, Liverpool, NSW, 2170, Australia.
Verena WallyEB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology & Allergology, University Hospital of the Paracelsus Medical University, 5020, Salzburg, Austria. v.wally@salk.at.
EB House Austria · ATParacelsus Medical University · ATAustrian Red Cross · ATIngham Institute · AUJohannes Kepler University of Linz · ATUNSW Sydney · AUWestern Sydney University · AU

Funding

Austrian Science Fund FWF P 29343
6 · The paper itself

Abstract

backgroundCutaneous squamous cell carcinomas (cSCC) are the primary cause of premature deaths in patients suffering from the rare skin-fragility disorder recessive dystrophic epidermolysis bullosa (RDEB), which is in marked contrast to the rarely metastasizing nature of these carcinomas in the general population. This remarkable difference is attributed to the frequent development of chronic wounds caused by impaired skin integrity. However, the specific molecular and cellular changes to malignancy, and whether there are common players in different types of aggressive cSCCs, remain relatively undefined.

methodsMiRNA expression profiling was performed across various cell types isolated from skin and cSCCs. Microarray results were confirmed by qPCR and by an optimized in situ hybridization protocol. Functional impact of overexpression or knock-out of a dysregulated miRNA was assessed in migration and 3D-spheroid assays. Sample-matched transcriptome data was generated to support the identification of disease relevant miRNA targets.

resultsSeveral miRNAs were identified as dysregulated in cSCCs compared to control skin. These included the metastasis-linked miR-10b, which was significantly upregulated in primary cell cultures and in archival biopsies. At the functional level, overexpression of miR-10b conferred the stem cell-characteristic of 3D-spheroid formation capacity to keratinocytes. Analysis of miR-10b downstream effects identified a novel putative target of miR-10b, the actin- and tubulin cytoskeleton-associated protein DIAPH2.

conclusionThe discovery that miR-10b mediates an aspect of cancer stemness - that of enhanced tumor cell adhesion, known to facilitate metastatic colonization - provides an important avenue for future development of novel therapies targeting this metastasis-linked miRNA.

Indexed as

Carcinoma, Squamous CellNeoplastic Stem CellsSkin NeoplasmsCells, CulturedEpidermolysis Bullosa DystrophicaGene Expression Regulation, NeoplasticHumansKeratinocytesMicroRNAsNeoplasm InvasivenessPrimary Cell CultureMicroRNAsMIRN10 microRNA, humanCancer stem cellEpidermolysis bullosaMetastasismiR-10bSquamous cell carcinoma

Identifiers

PMID32276641
PMCPMC7146875
OpenAlexW3016201288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.